Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.49 |
| ▸ | ESR1 | P03372 | 6/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3173300 | 0.88 | ESR2 (0.51) | SLC6A4SLC6A2SLC6A3ESR2ESR1 | |
| SCHEMBL3173307 | 0.88 | ESR2 (0.51) | SLC6A4SLC6A2SLC6A3ESR2ESR1 | |
| SCHEMBL5478613 | 0.83 | ESR2 (0.69) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL8568671 | 0.83 | ESR2 (0.69) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL11134743 | 0.82 | CYP2A6 (0.43) | SLC6A4SLC6A2SLC6A3ESR2ESR1 | |
| SCHEMBL11134749 | 0.82 | CYP2A6 (0.43) | SLC6A4SLC6A2SLC6A3ESR2ESR1 | |
| SCHEMBL11138918 | 0.81 | CYP1A2 (0.46) | SLC6A4SLC6A2SLC6A3ESR2ESR1 | |
| SCHEMBL11138912 | 0.81 | CYP1A2 (0.46) | SLC6A4SLC6A2SLC6A3ESR2ESR1 | |
| SCHEMBL11139987 | 0.81 | ALDH1A1 (0.43) | SLC6A4SLC6A2SLC6A3ESR2ESR1 | |
| SCHEMBL11139989 | 0.81 | ALDH1A1 (0.43) | SLC6A4SLC6A2SLC6A3ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | SLC6A4 3428/4885SLC6A2 3165/4885SLC6A3 3498/4885 |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | SLC6A4 3428/4885SLC6A2 3165/4885SLC6A3 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.